XENETIC BIOSCIENCES, INC. Increase (Decrease) in Accounts Receivable
XENETIC BIOSCIENCES, INC. (XBIO) reported Increase (Decrease) in Accounts Receivable of $0 for the 12-month period ending 2018-12-31, per its 10-K filed 2019-03-29.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsReceivable · last filed 2019-03-29
- XENETIC BIOSCIENCES, INC. increase (decrease) in accounts receivable for the quarter ending 2018-12-31 was $0.00.
- XENETIC BIOSCIENCES, INC. increase (decrease) in accounts receivable for the quarter ending 2018-09-30 was $0.00.
- XENETIC BIOSCIENCES, INC. increase (decrease) in accounts receivable for the quarter ending 2018-06-30 was $0.00.
- XENETIC BIOSCIENCES, INC. increase (decrease) in accounts receivable for the quarter ending 2018-03-31 was $0.00, a 100.00% decline year-over-year.
- XENETIC BIOSCIENCES, INC. increase (decrease) in accounts receivable for fiscal 2018 was $0.00.
- XENETIC BIOSCIENCES, INC. increase (decrease) in accounts receivable for fiscal 2017 was -$3.00M, a 200.00% decline from fiscal 2016.
- XENETIC BIOSCIENCES, INC. increase (decrease) in accounts receivable for fiscal 2016 was $3.00M.
- XENETIC BIOSCIENCES, INC. increase (decrease) in accounts receivable for fiscal 2015 was $0.00.
| Period end | Increase (Decrease) in Accounts Receivable 3 month | Increase (Decrease) in Accounts Receivable 6 month | Increase (Decrease) in Accounts Receivable 7 month | Increase (Decrease) in Accounts Receivable 9 month | Increase (Decrease) in Accounts Receivable 10 month | Increase (Decrease) in Accounts Receivable 12 month | Increase (Decrease) in Accounts Receivable 19 month | Increase (Decrease) in Accounts Receivable 22 month |
|---|---|---|---|---|---|---|---|---|
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-29 | $0.00 derived: sum of 2 quarters · filed 2019-03-29 | $0.00 derived: sum of 3 quarters · filed 2019-03-29 | $0.00 10-K · filed 2019-03-29 | ||||
| 2018-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-09 | $0.00 derived: sum of 2 quarters · filed 2018-11-09 | $0.00 10-Q · filed 2018-11-09 | -$5.96M derived: sum of 4 quarters · filed 2019-03-29 | ||||
| 2018-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-10 | $0.00 10-Q · filed 2018-08-10 | -$5.96M derived: sum of 3 quarters · filed 2019-03-29 | -$6.00M derived: sum of 4 quarters · filed 2019-03-29 | ||||
| 2018-03-31 | $0.00 10-Q · filed 2018-05-15 | -$5.96M derived: sum of 2 quarters · filed 2019-03-29 | -$6.00M derived: sum of 3 quarters · filed 2019-03-29 | -$6.00M derived: sum of 4 quarters · filed 2019-03-29 | ||||
| 2017-12-31 | -$5.96M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-29 | -$6.00M derived: sum of 2 quarters · filed 2019-03-29 | -$6.00M derived: sum of 3 quarters · filed 2019-03-29 | -$3.00M 10-K · filed 2019-03-29 | ||||
| 2017-09-30 | -$42.50K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-09 | -$42.50K derived: sum of 2 quarters · filed 2018-11-09 | $2.96M 10-Q · filed 2018-11-09 | $5.96M derived: sum of 4 quarters · filed 2018-11-09 | ||||
| 2017-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-10 | $3.00M 10-Q · filed 2018-08-10 | $6.00M derived: sum of 3 quarters · filed 2018-08-10 | $6.00M derived: sum of 4 quarters · filed 2018-08-10 | ||||
| 2017-03-31 | $3.00M 10-Q · filed 2018-05-15 | $6.00M derived: sum of 2 quarters · filed 2018-05-15 | $6.00M derived: sum of 3 quarters · filed 2018-05-15 | $6.00M derived: sum of 4 quarters · filed 2018-05-15 | ||||
| 2016-12-31 | $3.00M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-30 | $3.00M derived: sum of 2 quarters · filed 2018-03-30 | $3.00M derived: sum of 3 quarters · filed 2018-03-30 | $3.00M 10-K · filed 2018-03-30 | ||||
| 2016-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-14 | $0.00 derived: sum of 2 quarters · filed 2017-11-14 | $0.00 10-Q · filed 2017-11-14 | |||||
| 2016-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-14 | $0.00 10-Q · filed 2017-08-14 | ||||||
| 2016-03-31 | $0.00 10-Q · filed 2017-05-15 | |||||||
| 2015-12-31 | $0.00 10-K · filed 2017-03-31 | |||||||
| 2013-11-30 | $5.90K 10-Q · filed 2014-01-10 | $13.83K derived: sum of 2 quarters · filed 2014-01-10 | $28.10K derived: sum of 3 quarters · filed 2014-01-10 | $116.81K derived: sum of 4 quarters · filed 2014-01-10 | ||||
| 2013-08-31 | $7.93K derived: 10-K 12 month − 10-Q 9 month · filed 2013-11-27 | $22.20K derived: sum of 2 quarters · filed 2013-11-27 | $110.90K derived: sum of 3 quarters · filed 2013-11-27 | $77.94K 10-K · filed 2013-11-27 | ||||
| 2013-05-31 | $14.27K derived: 10-Q 9 month − 10-Q 6 month · filed 2013-07-17 | $102.97K derived: sum of 2 quarters · filed 2013-07-17 | $70.01K 10-Q · filed 2013-07-17 | $43.37K derived: sum of 4 quarters · filed 2014-01-10 | -$29.10K 10-Q · filed 2013-07-17 | |||
| 2013-02-28 | $88.70K derived: 10-Q 6 month − 10-Q 3 month · filed 2013-04-22 | $55.74K 10-Q · filed 2013-04-22 | $29.10K derived: sum of 3 quarters · filed 2014-01-10 | -$7.33K derived: sum of 4 quarters · filed 2014-01-10 | -$43.37K 10-Q · filed 2013-04-22 | |||
| 2012-11-30 | -$32.96K 10-Q · filed 2014-01-10 | -$59.60K derived: sum of 2 quarters · filed 2014-01-10 | -$96.03K derived: sum of 3 quarters · filed 2014-01-10 | -$124.38K derived: sum of 4 quarters · filed 2014-01-10 | ||||
| 2012-08-31 | -$26.64K derived: 10-K 12 month − 10-Q 9 month · filed 2013-11-27 | -$63.07K derived: sum of 2 quarters · filed 2013-11-27 | -$91.42K derived: sum of 3 quarters · filed 2013-11-27 | -$99.11K 10-K · filed 2013-11-27 | ||||
| 2012-05-31 | -$36.43K derived: 10-Q 9 month − 10-Q 6 month · filed 2013-07-17 | -$64.78K derived: sum of 2 quarters · filed 2013-07-17 | -$72.47K 10-Q · filed 2013-07-17 | -$72.47K 10-Q · filed 2012-07-16 | ||||
| 2012-02-29 | -$28.35K derived: 10-Q 6 month − 10-Q 3 month · filed 2013-04-22 | -$36.04K 10-Q · filed 2013-04-22 | -$36.04K 10-Q · filed 2012-04-24 | |||||
| 2011-11-30 | -$7.69K 10-Q · filed 2013-01-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |